Mission AD Study (sponsored by Eisai & Biogen)

The Wisconsin Alzheimer’s Disease Research Center is currently recruiting participants for a clinical research study investigating whether Elenbecestat (E2609, a BACE inhibitor) is superior to placebo in slowing disease progression (disease getting worse) in subjects age 50-85 years old with early Alzheimer’s disease. This research will also continue to study if Elenbecestat is safe and well tolerated.

The study involves coming to the University of Wisconsin-Madison for 13 study visits. Each visit will last between 2 to 6 hours. Some of the study procedures include blood draws, questionnaires, physical and neurological exams, MRI scans, PET scans, and electrocardiograms. You might need to make more than one trip in visits involving brain imaging: Magnetic Resonance Imaging (MRI), Positron Emission Topography (PET) scan or Cerebral Spinal Fluid (CSF) collection.

study contact